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ABSTRACT 
 
Tuberculosis, caused by the Mycobacterium tuberculosis (Mtb), is the infectious disease 
responsible for the highest number of deaths worldwide. Herein, 22 new N-oxide-
containing compounds were synthesized followed by in vitro and in vivo evaluation of 
their antitubercular potential against Mtb. Compound 8 was found to be the most 
promising compound, with MIC90 values of 1.10 and 6.62 μM against active and non-
replicating Mtb, respectively. Additionally, we carried out in vivo experiments to confirm 
the safety and efficacy of compound 8; the compound was found to be orally bioavailable 
and highly effective leading to the reduction of the number of Mtb to undetected levels in 
a mouse model of infection. Microarray-based initial studies on the mechanism of action 
suggest that compound 8 blocks the process of translation. Altogether, these results 
indicated benzofuroxan derivative 8 to be a promising lead compound for the 
development of a novel chemical class of antitubercular drugs. 
 
Keywords: Mycobacterium tuberculosis, tuberculosis, antitubercular drug, N-oxide, 
furoxan, benzofuroxan.  
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INTRODUCTION 
Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB) in humans, is 
considered to be responsible for the highest number of deaths caused by infectious 
diseases worldwide in 2015. The World Health Organization (WHO) reported 9.6 million 
new cases and 2 million deaths worldwide in the same year.
1
 The high mortality rate of 
TB has even surpassed the deaths caused by human immunodeficiency virus (HIV). 
According to an estimation, one-third of the world population is infected with a latent 
form of TB,
2
 where the treatment is often ineffective owing to a lack of drugs with an 
ability to act in the dormant state of mycobacteria.
3,4
 
Furthermore, increased dissemination of multidrug-resistant (MDR), extensively drug-
resistant (XDR), and totally drug-resistant (TDR) strains poses a huge challenge to be 
overcome throughout the world in the fight against TB.
5–8
 
For the treatment, the WHO recommends a combination of isoniazid (INH), rifampicin 
(RMP), ethambutol (EMB), and pyrazinamide (PZA) for six months. In the cases 
involving resistance, the treatment can be extended up to 28 months and include the use 
of second-line drugs, such as fluoroquinolones, aminoglycosides, D-cycloserine (DCS), 
and linezolid (LZD) among others.
9–11
 The current treatment suffers from several 
limitations, including prolonged standard regimen, high rate of treatment discontinuation, 
adverse effects, toxicity, drug–drug interactions, and a lack of effectiveness against the 
latent mycobacteria.
2,12–16
 
Over the past few years, limited but significant progress in the development of drug 
candidates against TB has been achieved. After a gap of more than 50 years without new 
drugs approved for TB, the United States Food and Drug Administration (FDA) approved 
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bedaquiline (Bdq, SIRTURO,
®
 Janssen; Beerse, Belgium) in 2012 for the treatment of 
MDR-TB. The literature in the past 5 years has witnessed significant advances in the 
development of other compounds with potent antitubercular activity.
17–20
 In this regard, 
several drug candidates were moved toward clinical trials, such as sutezolid, posizolid, 
delamanid, and pretomanid.
21,22
 Nevertheless, Mtb strains, resistant to the new 
compounds, have already been reported,
23–25
 reinforcing the urgency to develop more 
potent and a larger number of novel drugs for the treatment of TB.
11
 
We have previously reported a series of furoxan derivatives with potent activity against 
Mtb, including MDR strains. Specifically, the compound, (E)-4-(4-((2-
isonicotinoylhydrazono)methyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide 
(Figure 1) could inhibit 90% growth of Mtb H37Rv strain at a concentration of 1 μM. In 
addition, we characterized that the antitubercular activity of the above-mentioned furoxan 
derivative was related to its ability to generate nitric oxide (NO) following 
biotransformation.
26
 
Motivated by preliminary promising results obtained with the furoxan derivatives, we 
designed new heterocyclic analogs containing the N-oxide subunit, including amide-
furoxans (series 1), benzofuroxans (series 2), and quinoxaline, 1,4-di-N-oxide (QdNO) 
(series 3, Figure 1). Furoxans, benzofuroxans, and QdNO derivatives represent important 
scaffolds in medicinal chemistry due to their wide spectrum of biological activities,
27
 
including antitubercular activity.
28
 The antimycobacterial activity of these compounds is 
attributed to the generation of reactive oxygen species (ROS) following their 
biotransformation.
29–31
 Specifically for quinoxalines, earlier studies have reported that 
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these compounds lead to increased levels of ROS under hypoxic conditions, which could 
contribute to interesting properties against latent TB.
32–34
  
The ROS play a crucial role in the pathogenesis of TB. Several studies have demonstrated 
the relationship between the levels of ROS produced by immune cells and the 
susceptibility of patients to several species of the Mycobacterium genus.
35,36
 Furthermore, 
ROS exert many-fold effects during TB. For example, increased ROS levels can lead to 
an inhibition of Mtb growth, damage to cellular components, such as lipids, proteins, and 
nucleic acids, and activate macrophage-mediated inflammatory activity.
37–40
 The high 
levels of ROS can also induce apoptosis of macrophages (host for tubercle bacilli), 
thereby preventing the growth and replication of the bacilli.
41
 Therefore, the design of 
new compounds that could act by increasing the levels of ROS and perturbing 
mycobacterial redox homeostasis seems to be a promising strategy for combating TB.
42–44
 
In a continuing effort to develop new drug candidates for the treatment of TB, we herein 
describe the design, synthesis, and biological activities of a series of heterocyclic 
compounds containing N-oxide as antitubercular compounds. 
 
RESULTS AND DISCUSSION  
Chemistry 
Twenty-two novel compounds containing the N-oxide subunit were synthesized 
according to the synthetic methodologies presented in Schemes 1, 2, and 3. 
The amide-furoxan derivatives (1, 2) were synthesized according to the previously 
described methods.
45,46
 The furoxan derivative (2) was allowed to react with 2-, 3- , or 4-
hydroxybenzaldehyde in dichloromethane medium, using 1,8-diazabicyclo[5.4.0]undec-
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7-ene (DBU) as the base, leading to the formation of the furoxan derivatives containing 
an aldehyde group (3a–c).47 Then, a condensation reaction of the aldehyde derivatives 
with isonicotinohydrazide was performed in ethanolic medium catalyzed by an acid to 
generate the hybrid furoxan derivatives (4a–c, Scheme 1). 
The benzofuroxan derivative containing an aldehyde group (7) was obtained according to 
a previously reported methodology.
48
 The compound was allowed to react with different 
aromatic hydrazides through the same condensation reaction described above leading to 
the formation of benzofuroxan derivatives (8–17, Scheme 2). The 1H and 13C nuclear 
magnetic resonance (NMR) spectra of these compounds displayed protons and carbon 
signals from the benzofuroxan nucleus as broad peaks, indicating a benzofuroxan 
tautomerism.
27,31
 
The dioxolan-benzofuroxan derivative (18) was obtained from the reaction between 
compound (7) and ethylene glycol.
49
 The quinoxaline derivatives were obtained through a 
variation of the Beirut reaction,
50–52
 wherein the dioxolan–benzofuroxan derivative (18) 
reacted with the appropriate nitrile derivatives in dichloromethane medium. Potassium 
carbonate (K2CO3) was utilized as a catalyst
53
 leading to the generation of quinoxaline 
derivatives (19–26). Compound (28) was synthesized from quinoxaline (19), which was 
submitted to a cyclic acetal hydrolysis followed by its reaction with isonicotinohydrazide 
through a condensation reaction (Scheme 3).
54
 
All compounds were characterized by elemental analysis, infrared (IR) spectroscopy, 
mass spectrometry, and 
1
H and 
13
C NMR. Furthermore, all compounds were analyzed by 
high-pressure liquid chromatography (HPLC) and their purity was confirmed to be 
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superior to 98.5%. Experimental logP values and melting points were determined for the 
final compounds. 
 
Biological studies 
The antitubercular activity of compounds containing N-oxide (4a–c, 8–17, 19–26, and 
28) was performed using Mtb H37Rv ATCC 27294 strain. The resazurin microtiter assay 
(REMA) was employed as described previously.
26,55
 The results were expressed as 
minimum inhibitory concentration (MIC90) and compounds showing MIC90 values below 
10 μM were selected for further characterization. The potential cytotoxicity was 
evaluated using human lung fibroblast, MRC–5 according to a previously reported 
methodology
26,56
 and the results were expressed as IC50 values. The selectivity index (SI) 
of the tested compounds was calculated through the ratio between IC50 and MIC90. The 
compounds that reported SI ≥ 10 were considered promising for further studies according 
to the cutoff value established.
56,57
 Potential anaerobic activity of the best compounds was 
evaluated using the method described by Cho et al., 2007.
58
 
The analysis of the spectrum of biological activity of the compounds was performed 
through determination of MIC90 values against Escherichia coli (ATCC 25922) and 
Staphylococcus aureus (ATCC 29213) by measuring the optical density (OD) at 570 nm 
(OD570) after 16 h and against Candida albicans (ATCC 10231) at OD570 nm after 48 h.  
The compounds were also tested against Mtb H37Rv isogenic strains monoresistant to 
RMP (ATCC 35838); INH (ATCC 35822); streptomycin (SM, ATCC 35820); 
capreomycin (CAP), moxifloxacin (MOX), and BDQ (strains from the University of 
Illinois at Chicago-Institute for Tuberculosis Research) by microdilution technique 
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multiple antigen blot assay (MABA).
59
 Following this step, we selected the best 
compound (compound 8) for further studies. 
Due to the ability of Mtb to survive inside the macrophages, we decided to investigate 
whether compound 8 could inhibit the growth of Mtb H37Rv strain in J774A.1 
macrophage cell line. Furthermore, time-kill experiments were performed for up to 15 
days to evaluate the bactericidal profile of compound 8. 
Some earlier reports
60,61
 indicated that the growth of mycobacteria can be affected by the 
presence of ions, nutrients, and pH of the medium. With this regard, different conditions 
of culture medium were analyzed by MABA. These included (a) adjusting the culture 
medium to pH 6.0; (b) including 4% bovine serum albumin (BSA); and (c) the 
supplementation of 10% fetal bovine serum (FBS). The slightly acidic pH (pH 6.0) was 
selected as the pH compatible to the growth of Mtb and corresponding to the time of 
fusion of Mtb-containing phagosomes with lysosomes. One of the physiological functions 
of albumin (synthesized in the liver) is to transport of poorly soluble molecules of both 
endogenous and exogenous origin.
62
 Albumin binding constitutes an essential 
pharmacological parameter that affects the mechanism of action of antibiotics in 
humans.
63
 We utilized FBS, as it serves as a growth factor for mammalian cells and might 
interfere with the antitubercular action of some compounds. 
Preliminary ADMET (abbreviation for absorption, distribution, metabolism, and 
excretion) studies were performed for compound 8 using the following in vitro assays: 
chemical stability assay, plasma protein binding assay, caco–2 permeability assay, 
cytochrome P450 inhibition assay, and hepG2 cytotoxicity. Additionally, we 
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characterized the mutagenicity of compound 8 through the micronucleus assay using the 
mouse peripheral blood reticulocytes. 
To ensure a greater stability and improved solubility, compound 8 was evaluated in an in 
vivo assay using a pharmaceutical formulation. The nanostructured lipid system (ME) 
was synthesized as described by our group previously,
64
 with the following composition: 
10% oil phase (cholesterol), 10% surfactant (a mixture of soy phosphatidylcholine, 
sodium oleate, and Eumulgin® HRE 40 [polyoxyl 40 castor oil-hydrogenated]; 3:6:8), 
and 80% aqueous phase (phosphate buffer, pH 7.4). The compounds studied were 
incorporated at the desired concentration for the in vivo experiments by mass 
solubilization at the respective volume and sonicated for 3 min in the batch mode at 15% 
amplitude. The ME containing compound 8 was analyzed for tolerability and oral 
bioavailability following the treatment of female BALB/C mice infected with Mtb. 
Microarrays have been used to define successfully the mechanism of action (MOA) of 
antitubercular compounds.
65
 Therefore, a microarray analysis was performed to obtain an 
unbiased view of the MOA of compound 8. 
 
In Vitro Antimycobacterial Activity 
The ability of Mtb to remain dormant serves as the predominant factor that contributes to 
precluding sterilization with antibiotic therapy and promotes the development of 
antibiotic resistance.
66,67
 Therefore, an ideal antitubercular drug should (i) reduce the 
duration of treatment; (ii) be active against resistant strains; (iii) not interfere with other 
TB drugs and antiretrovirals; and (iv) be active against “dormant” bacilli.10 
10 
 
Recently, our research group has identified the compound, (E)-4-(4-((2-
isonicotinoylhydrazono)methyl)phenoxy)-3-(phenylsulfonyl)-1,2,5-oxadiazole 2-oxide as 
a promising antitubercular drug candidate.
26
 To optimize its antimycobacterial activity, 
we designed novel heterocyclic compounds containing N-oxide analogs of the parent 
compound, which comprised the following heterocyclic moieties: amide–furoxan (series 
1, 4a–c), benzofuroxan (series 2, 8–17), and quinoxaline 1,4-di-N-oxide (series 3, 19–26, 
28). The amide–furoxan derivatives (4a–c) were selected to evaluate whether the 
replacement of the phenylsulfonyl group from the parent compound by an amide group 
would increase the antitubercular activity and/or decrease the cytotoxicity. The three 
amide–furoxan regioisomers (4a–c) displayed an improved antitubercular activity than 
the parent compound.
26
 The compounds from series 1 exhibited MIC90 values around 0.4 
μM against actively growing Mtb H37Rv strain (Table 1).  
The benzofuroxan moiety (series 2, 8–17) was selected due to its possible ability to 
generate ROS after its metabolism.
30
 The structural design of the series under the study 
was based on the isosteric replacement of substituents attached at the para position on the 
phenyl ring. These included hydrogen, nitro, tert-butyl, amino, and hydroxyl groups. 
Furthermore, we evaluated the substitution of the phenyl ring by a pyridine ring owing to 
the presence of heterocyclic pyridine ring in the structure of several antituberculosis 
drugs and bioactive compounds, such as INH, BDQ, and ethionamide.
68
 As expected, the 
replacement of the phenyl ring of compound 9 by a pyridine ring in compound 8 led to a 
seven-fold increase in the antituberculosis activity (MIC90 = 1.1 μM, Table 1). 
Among the benzofuroxan series, our group could identify the compound, (E)-6-((2-
isonicotinoylhydrazono)methyl)benzo[c][1,2,5]oxadiazole 1-oxide (8) as the lead 
11 
 
benzofuroxan derivative with MIC90 values of 1.1 and 6.6 μM for actively growing and 
dormant Mtb, respectively. The observed nearly equimolar effects against replicating and 
non-replicating Mtb attributed to the small difference in MIC90 values is considered as an 
attractive characteristic. Such differences are rarely observed but highly desired and 
beneficial. 
Moreover, our data revealed that the presence of bulky groups, such as tert-butyl (10, 
MIC90 = 3.9 μM) and electron-withdrawing groups, such as nitro (11, MIC90 = 5.3 μM), 
led to an improvement in antituberculosis activity of the analyzed compounds. 
Compound 9, un-substituted phenyl, presented a MIC90 value of 8.3 μM, while the 
hydroxyl regioisomers (12–14) presented MIC90 values greater than 62 μM. Amino 
derivatives (15–17) also exhibited a reduction in the antitubercular activity in comparison 
to the non-substituted compounds 9; however, these compounds reported MIC90 values 
(12.3– 27.9 μM) lower than those containing a hydroxyl substitution (Table 1).  
With respect to the quinoxaline, 1,4-di-N-oxide series, we evaluated the influence of 
electron-withdrawing and electron-donating groups on the phenyl ring for its 
antitubercular activity. We also performed an isosteric substitution of the phenyl ring by 
furan (25) and thiophen (26) moieties. For quinoxaline-phenyl derivatives (19–24), the 
MIC90 values ranged from 12.0 to 30.8 μM, implying a contribution of the presence of 
substitution at the para position of the phenyl ring to the antituberculosis activity. Since 
compound 19 was devoid of any substituents, it displayed a lower potency among the 
phenyl quinoxaline derivatives with MIC90 = 30.8 μM. On the other hand, compound 22, 
with a methoxyl group in the para position, displayed the lowest MIC90 value among the 
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phenyl quinoxaline series. Nevertheless, we could not observe a clear and accurate 
structure–activity relationship regarding the electronic properties of the substituents. 
For compounds 25 and 26, the isosteric replacement of the phenyl group by a furan or 
thiophen ring led to a significant increase in the antitubercular activity. Compounds 25 
and 26 exhibited MIC90 values of 5.2 and 12.1 μM, respectively. Furthermore, we 
synthesized a quinoxaline derivative containing an N-acylhydrazone subunit (28); the 
antitubercular activity of this compound decreased in comparison to the previous 
quinoxalines exhibiting MIC90 value of 39.7 μM. 
 
Further in Vitro Biological Profiling of Selected Compounds 
We evaluated the cytotoxicity of the final compounds against MRC–5 cell lines. This cell 
line is derived from healthy human lung fibroblasts and is widely utilized for the 
phenotypic screening of antitubercular drugs.
69–71
 
The data obtained in the cytotoxicity studies of the amide–furoxan series (4a–c) indicated 
a high selectivity of these compounds against Mtb. All three regioisomers exhibited high 
IC50 values (>854.0 μM), thereby leading to high SI values, which ranged from 2,033 to 
3,205 (Table 1). 
Regarding the cytotoxicity studies of the benzofuroxan series, we observed IC50 values 
ranging from 25 to 841 μM in MRC–5 cell lines. The most active benzofuroxan 
derivative (8) presented an IC50 value of 519 μM; however, the compound 17 was found 
to be less cytotoxic among the benzofuroxan series with an IC50 value of 841 μM. 
Compounds 11 to 14 did not display promising antitubercular activity (MIC90 > 62 μM) 
and consequently were excluded from the cytotoxicity studies. Rather, compound 8 was 
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selected for further experiments, as it possessed the highest potency against Mtb and the 
lowest cytotoxicity.  
Compounds from quinoxaline series were significantly more cytotoxic in MRC–5 cells 
with their IC50 values ranging from 13 to 67 μM, thereby resulting in low SI (<6.8) values 
and making them less attractive candidates as antitubercular agents.
56
 
The data obtained from MIC90 in different conditions (Table 2) depicted no significant 
differences between MIC90 under normal and others conditions. These conditions 
included (a) adjusting the pH of the culture medium to 6.0; (b) including 4% BSA; and 
(c) supplementation of 10% FBS. 
Antimicrobials are classified as containing narrow, intermediate, or broad spectrum of 
activity. Tuberculosis is a chronic infection, the treatment of which requires a drug with 
narrow spectrum, such as INH. All amide–furoxan and benzofuroxan (8, 11, 14, and 17) 
derivatives were checked against S. aureus, E. coli, and C. albicans. No antimicrobial 
activity was detected up to a maximum concentration of 200 μM. 
In terms of cross-resistance, compound 8 displayed equipotent activity (<two-fold change 
in MIC90) against all drug-sensitive and monoresistant strains of Mtb tested, suggesting a 
novel MOC or inhibition of a shared target distinct binding site by the compound (Table 
3). In contrast, amide–furoxan series (4a–c) was inactive against half of the 
monoresistant strains tested and therefore was not selected for further studies. 
We utilized J774A.1, a macrophage cell line, to study the intracellular inhibition of Mtb 
using the drugs under analysis. Our group observed that compound 8 exhibited a high 
intracellular inhibition at all concentrations tested (around 90%). However, similar to 
RMP, we could not verify the dose-dependent inhibition at different concentrations 
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(Figure 2). In time-kill kinetic experiments, compound 8 was observed to be bactericidal 
with an early bactericidal effect. Noteworthy, compound 8 could sterilize the cultures 
after 48 h of exposure (about of 6.7 log10, Figure 3). 
 
Preliminary ADMT Studies of Compound 8 
On the basis of the promising biological results described above for compound 8, we 
conducted stability and ADMT studies to assess its drug-like properties, such as 
absorption, distribution, metabolism, and excretion. To analyze the chemical stability of 
the compound, we conducted an in vitro assay under two pH conditions (5.5 and 7.4) to 
mimic the environment of a macrophage phagolysosome (pH 4.5–6.2)72,73 and the neutral 
plasma (pH 7.4). At pH 5.5 and 7.4, the compound 8 exhibited a good stability (Figure 
4); however, a reduction of 20% was detected at both pH values after 10 h. Interestingly, 
the concentration of compound 8 increased to 67 and 75% at pH 5.5 and 7.4, respectively, 
after 24 h. The degradation rates of compound 8 were calculated by HPLC-UV; however, 
we did not characterize the degradation products. These results indicated that the 
compound 8 exhibited a high stability in the physiological pH range in the target areas of 
bacteria, namely, blood and phagolysosome. 
The in vitro ADMT properties for compound 8 are listed in Table 4. The benzofuroxan 
derivative reported 46.5% unbound fraction when an in vitro plasma protein binding 
assay was conducted. The findings of the study with compound 8 on the inhibition of 
cytochrome P450 isoforms depicted no potential for inhibition, presenting IC50 values 
greater than 15.0 µM in all isoforms tested. The studies in the Caco–2 cell line 
demonstrated a good permeability profile. The cytotoxicity study conducted in HepG2 
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cells reported an IC50 of 16.0 µM and an SI of 14.5. We also performed the micronucleus 
assay using mouse peripheral blood reticulocytes for compound 8 to evaluate its intrinsic 
mutagenic activity. The results indicated that compound 8 was not genotoxic at all 
concentrations tested (Figure 5).  
 
Tolerability, Oral Bioavailability, and Efficacy of Compound 8 in Mice 
In vivo oral bioavailability, toxicology, infection, and treatment studies were performed 
to ensure the safety and efficacy of compound 8. 
For toxicology studies, the mice were monitored daily for 10 days, receiving one daily 
oral dose (by gavage, 200 mg/kg body weight), and the behavior parameters (hippocratic 
screening) were evaluated. No significant variation in the behavior of mice was observed 
during the period of 10 days. Changes in the weight of organs (heart, lungs, spleen, 
kidneys, and liver) were evaluated using analysis of variance (ANOVA) and Dunnett’s 
test, establishing a p-value < 0.05 as the significant level. No statistically significant 
difference was observed between the drug-treated and control groups. To probe the 
potential liver damage, the levels of liver transaminases were checked in the plasma that 
reported no significant differences for alanine aminotransferase (Figure 6a), aspartate 
aminotransferase (Figure 6b), and alkaline phosphatase (Figure 6c) between the treated 
and control groups. Similarly, we evaluated the levels of urea in blood samples to assess 
the potential changes in kidney function. Here, a significant difference was observed for 
the group treated with RMP-ME, when compared to the control group (Figure 6d). The 
study on the oral bioavailability of compound 8 displayed an inhibition of Mtb growth in 
mice plasma (Table 5). 
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Histology of liver (Figure 7) and kidneys (Figure 8) revealed similar morphology in all 
the groups, implying that no gross abnormalities were caused by the treatments. 
The efficacy of compound 8 was analyzed by infecting the mice with Mtb H37Rv strain 
followed by subjecting the infected animals to the treatment with compound 8 or vehicle. 
The homogenized lung samples were plated at a dilution of 1:100 to 1:10,000,  at which 
no growth of Mtb colonies was observed. Therefore, the homogenized lung samples were 
re-inoculated on agar plates in undiluted form and at 1:10 dilution; however, again, no 
colony was observed (Figure 9). Control experiments with vehicles, RPM, and RPM-CE 
behaved as expected (Figure 9). 
 
Mode of Action Studies 
Although the antitubercular activity of the benzofuroxan derivative 8 was originally 
attributed to its potential to generate and release nitric oxide (NO), we believe this to be 
no longer the case, since the compound could not release NO in the Griess assay (a 
chemical test to analyze nitrite ions in a solution, data not shown). An alternative 
mechanism was proposed as mentioned below. 
Microarray analysis of Mtb treated with compound 8 or vehicle control revealed a 
significant up-regulation in the majority of ribosomal genes as well as all genes encoding 
subunits of the ATP synthase (Figure 10 and Supplementary Table S1). This included 
EF-G, which induces GTP-dependent translocation of nascent peptide chains from the A- 
to the P-site in the ribosome and EF-Tu, which promotes GTP-dependent binding of 
aminoacylated tRNAs to the A-site in ribosomes. No up-regulation of heat shock proteins 
was observed, which in fact demonstrated a down-regulation of hsp, htrA, and hspR 
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(Supplementary Table S1). Similarly, up-regulation of ribosomal proteins was observed 
upon treatment of Mtb with the inhibitors of protein synthesis. Our data indicated an up-
regulation of a large number of operons as well as single genes encoding ribosomal 
proteins, which in turn suggested that compound 8 could affect protein synthesis by 
inhibiting the ribosome. Boshoff and coworkers (2004)
65
 divided the protein synthesis 
inhibitors into two classes on the basis of their effect on the expression of heat shock 
proteins (either no effect or up-regulation). Compound 8 did not increase the abundance 
of transcripts encoding heat shock proteins, and in fact, decreased the levels of three 
transcripts (hsp, htrA, and hspR). The results of the study on the inhibition of protein 
synthesis indicated compound 8 to behave more like an inhibitor of initiation of 
translation, such as tetracyclines, rather than an inhibitor of protein synthesis that leads to 
mis-translation, such as aminoglycosides. Further studies are required to define the exact 
MOA of compound 8, including its binding site and inhibition of the Mtb ribosome, ATP 
synthase, or other targets.  
 
CONCLUSIONS 
Twenty-two new N-oxide containing compounds were synthesized followed by in vitro 
and in vivo evaluation of their antitubercular activity against Mtb. The amide–furoxan 
series (4a–c) was observed to be the most promising compounds with MIC90 values 
around 0.40 μM against actively replicating Mtb and SI values ranging from 2033.3 to 
3204.7. The benzofuroxan series (8–17) also presented promising antitubercular activity, 
especially compound 8, which reported MIC90 value of 1.1 and 6.6 μM against actively 
growing and non-replicating Mtb, respectively. Compound 8 also displayed high activity 
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in the macrophage model of infection. In addition, in vivo studies employing the mouse 
model of infection demonstrated the sterilizing activity for compound 8. No detectable 
Mtb was observed in the lungs of mice treated, while control mice displayed expected 
number of colony forming units (CFUs). Altogether, these findings highlighted the 
benzofuroxan derivative 8 as a novel lead compound for designing antitubercular drug 
with sterilizing activity superior to rifampicin in the mouse model of infection. 
 
EXPERIMENTAL SECTION 
Chemistry 
Melting points (mp) were measured using an electrothermal melting point apparatus 
(SMP3; Bibby Stuart Scientific) or in a Mettler FP82+FP80 apparatus (Greifense, 
Switzerland). Infrared spectroscopy (KBr disc) were performed on a FTIR-8300 
Shimadzu or a Nicolet Nexu FTIR Thermo® spectrometer, and the frequencies are 
expressed in cm
-1
. The NMR for 
1
H and 
13
C of all compounds were performed on a 
Bruker Fourier with Dual probe 
13
C/
1
H (300-MHz) NMR spectrometer or Bruker 400 
Ultrashield
TM
 
13
C/
1
H (400-MHz) NMR spectrometer using deuterated chloroform 
(CDCl3) or dimethyl sulfoxide (DMSO-d6) as solvent and the chemical shifts were 
expressed in parts per million (ppm) relative to tetramethylsilane. The signal 
multiplicities are reported as singlet (s), doublet (d), doublet of doublet (dd), and 
multiplet (m). Elemental microanalysis (C, H and N) was performed on a Perkin-Elmer 
model 2400 analyzer or a CHN-900 Elemental Analyzer (LECO, Tres Cantos, Spain) and 
the data were within ± 0.4% of the theoretical values. HRMS (ESI
+
) data were acquired 
using a Bruker Maxis Impact® quadrupole time of flight tandem mass spectrometer (Q-
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TOF MS/MS) and the mass spectra values are reported as m/z. The compounds were 
purified on a chromatography column with silica gel (60 Å pore size, 35-75-µm particle 
size) and the following solvents were used as mobile phase: methanol, ethyl acetate, 
dichloromethane, hexane and petroleum ether in a flow rate of approximately 20 mL/min. 
The reaction progress of all compounds was monitored by thin-layer chromatography 
(TLC), which was performed on 2.0- by 6.0-cm
2
 aluminum sheets precoated with silica 
gel 60 (HF-254; Merck) to a thickness of 0.25 mm and revealed under UV light (265 
nm). All compounds were analyzed by HPLC, and their purity was confirmed to be 
greater than 98.5%. HPLC conditions: Shimadzu HPLC model CBM 20-A (Shimadzu®) 
equipped with UV-VIS detector (model SPD-20A), quaternary pumping system mobile 
phase (model LC-20AT), solvent degasser (model DGU-20As) and a Agilent® Eclipse 
XDB C-18 column (250mm x 27 4,6mm; 5μm). For HPLC method it was used an 
isocratic flow [methanol:water (75:25)]. Reagents and solvents were purchased from 
commercial suppliers. Compounds 3a-c,
45–47
 7,
48
 18, 19 and 28
54
 were prepared according 
to previously described methods. 
 
General procedure for the synthesis of compounds 4a-c and 8-17 
A solution of compound 3a-c or 7 (0.87 mmol) in 10 mL of ethanol and 3 drops of glacial 
acetic acid was stirred at room temperature for 20 min. Next, the appropriate aromatic 
hydrazide (0.106 g, 0.87 mmol) was added and the mixture was stirred for 12 h. The 
solvent was concentrated under reduced pressure and ice was added in order to precipitate 
the desired products. If necessary, the samples could be further purified by silica gel 
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column chromatography using ethyl acetate-methanol (98:2 v/v) as eluent to give the 
appropriate compound 4a-c, and 8-17 with variable yields. 
 
(E)-3-carbamoyl-4-((2-((2-isonicotinoylhydrazono)methyl)phenoxy)methyl)-1,2,5-
oxadiazole 2-oxide (4a). White powder; yield, 51%; mp, 226 to 229°C. IR Vmax (cm
-1
; 
KBr pellets): 3433 (NH2 amide), 3203 (N-H), 1669 (C=O amide), 1587 (C=N imine), 
1456 (N-O furoxan), 1344 (C-N aromatic), 1145 (C-O ether). 
1
H NMR (300 MHz, 
DMSO-d6, δ ppm) δ: 12.10 (1H; s; N-H), 8.79 (2H; d;), 8.51 (1H; s), 7.91 (1H; dd), 7.84 
(2H; d), 7.46 (1H; m), 7.25 (1H, d), 7.11 (1H, t), 5.54 (2H; s) ppm. 
13
C NMR (75 MHz, 
DMSO-d6, δ ppm) δ: 161.55, 156.36, 155.65, 155.24, 150.30, 144.04, 140.47, 131.84, 
125.85, 122.59, 121.87, 121.59, 113.36, 110.51 ppm. Anal. Calcd. (%) for C16H12N6O5: 
C: 52.18; H: 3.28; N: 22.82. Found: C: 52.25; H: 3.29; N: 22.90. HRMS: m/z (ESI
+
) = 
405.0918 [M + Na]
+
. 
 
(E)-3-carbamoyl-4-((3-((2-isonicotinoylhydrazono)methyl)phenoxy)methyl)-1,2,5-
oxadiazole 2-oxide (4b). White powder; yield, 59%; mp, 159 to 163°C. IR Vmax (cm
-1
; 
KBr pellets): 3439 (NH2 amide), 3201 (N-H), 1712 (C=O amide), 1591 (C=N imine), 
1485 (N-O furoxan), 1327 (C-N aromatic), 1147 (C-O ether). 
1
H NMR (300 MHz, 
DMSO-d6, δ ppm) δ: 12.09 (1H; s; N-H), 8.78 (2H; d), 8.46 (1H; s), 7.81 (3H; d), 7.41 
(3H; m), 5.48 (2H; s) ppm. 
13
C NMR (75 MHz, DMSO-d6, δ ppm) δ: 156.96, 150.22, 
147.97, 147.44, 142.63, 140.97, 132.70, 127.87, 122.48, 113.82, 113.14, 109.30, 105.24, 
102.74 ppm. Anal. Calcd. (%) for C16H12N6O5: C: 52.18; H: 3.28; N: 22.82. Found: C: 
52.27; H: 3.29; N: 22.90. HRMS: m/z (ESI
+
) = 405.0922 [M + Na]
+
. 
21 
 
 
(E)-3-carbamoyl-4-((4-((2-isonicotinoylhydrazono)methyl)phenoxy)methyl)-1,2,5-
oxadiazole 2-oxide (4c). White powder; yield, 67%; mp, 235 to 239°C. IR Vmax (cm
-1
; 
KBr pellets): 3.367 (NH2 amide), 3255 (N-H), 1708 (C=O amide), 1612 (C=N imine), 
1413 (N-O furoxan), 1255 (C-N aromatic), 1122 (C-O ether). 
1
H NMR (300 MHz, 
DMSO-d6, δ ppm) δ: 11.95 (1H; s; N-H), 8.77 (2H; d;), 8.43 (1H; s), 7.80 (2H; d), 7.71 
(2H; d), 7.14 (2H; d), 5.48 (2H; s) ppm. 
13
C NMR (75 MHz, DMSO-d6, δ ppm) δ: 
162.96, 162.33, 159.91, 156.34, 150.86, 149.52, 141.14, 129.65, 128.08, 122.14, 115.84, 
111.05 ppm. Anal. Calcd. (%) for C16H12N6O5: C: 52.18; H: 3.28; N: 22.82. Found: C: 
52.20; H: 3.28; N: 22.84. HRMS: m/z (ESI
+
) = 405.0913 [M + Na]
+
. 
 
(E)-6-((2-isonicotinoylhydrazono)methyl)benzo[c][1,2,5]oxadiazole 1-oxide (8). 
Yellow powder; yield, 85%; mp, 230 to 232 °C. IR Vmax (cm
-1
; KBr pellets): 3324 (N-H), 
3045 (NH2 amide), 1690 (C=O amide), 1600 (C=N imine), 1409 (N-O furoxan), 1273 (C-
N aromatic). 
1
H NMR (300 MHz, DMSO-d6, δ ppm) δ: 12.44 (1H; s), 8.80 (2H; d; J = 
5.7 Hz), 8.51 (1H; s), 8.03 (3H; m), 7.84 (2H; d; J = 6.0 Hz) ppm. 
13
C NMR (75 MHz, 
DMSO-d6, δ ppm) δ: 162.4, 150.6, 146.6, 140.2, 133.7, 130.8, 130.4, 130.1, 129.4, 121.8, 
114.3 ppm. Anal. Calcd. (%) for C13H9N5O3: C: 55.13; H: 3.20; N: 24.73. Found: C: 
55.22; H: 3.21; N: 24.78. HRMS: m/z (ESI
+
) = 306.0602 [M + Na]
+
. 
 
(E)-6-((2-benzoylhydrazono)methyl)benzo[c][1,2,5]oxadiazole 1-oxide (9). Yellow 
powder; yield, 80%; mp, 220 to 221 °C. IR Vmax (cm
-1
; KBr pellets): 3389 (N-H), 3041 
(NH2 amide), 1641 (C=O amide), 1533 (C=N imine), 1487 (N-O furoxan), 1300 (C-N 
22 
 
aromatic). 
1
H NMR (300 MHz, DMSO-d6, δ ppm) δ: 12.24 (1H; s), 8.52 (1H; s), 7.94 
(5H; m), 7.58 (3H; m) ppm. 
13
C NMR (75 MHz, DMSO-d6, δ ppm) δ: 163.4, 145.0, 
132.9, 132.1, 128.5, 127.8, 118.4, 113.5 ppm. Anal. Calcd. (%) for C14H10N4O3: C: 
59.57; H: 3.57; N: 19.85. Found: C: 59.65; H: 3.56; N: 19.88. 
 
(E)-6-((2-(4-(tert-butyl)benzoyl)hydrazono)methyl)benzo[c][1,2,5]oxadiazole 1-oxide 
(10). Yellow powder; yield, 89%; mp, 189 to 191 °C. IR Vmax (cm
-1
; KBr pellets): 3341 
(N-H), 3068 (NH2 amide), 1659 (C=O amide), 1532 (C=N imine), 1486 (N-O furoxan), 
1287 (C-N aromatic). 
1
H NMR (300 MHz, DMSO-d6, δ ppm) δ: 12.16 (1H; s), 8.51 (1H; 
s), 7.93 (4H; m), 7.56 (3H; d; J = 8.4 Hz), 1.32 (9H; s) ppm. 
13
C NMR (75 MHz, DMSO-
d6, δ ppm) δ: 160.3, 155.0, 144.7, 130.2, 127.7, 125.3, 118.3, 113.3, 56.0, 34.8, 30.9 ppm. 
Anal. Calcd. (%) for C18H18N4O3: C: 63.89; H: 5.36; N: 16.56. Found: C: 63.95; H: 5.37; 
N: 16.59. 
 
(E)-6-((2-(4-nitrobenzoyl)hydrazono)methyl)benzo[c][1,2,5]oxadiazole 1-oxide (11). 
Yellow powder; yield, 78%; mp, 261 to 262 °C. IR Vmax (cm
-1
; KBr pellets): 3373 (N-H), 
3073 (NH2 amide), 1673 (C=O amide), 1525 (C=N imine), 1400 (N-O furoxan), 1357 (C-
N aromatic). 
1
H NMR (300 MHz, DMSO-d6, δ ppm) δ: 12.50 (1H; s), 8.52 (1H; s), 8.39 
(2H; d; J = 8.8 Hz), 8.17 (2H; d; J = 8.8 Hz), 7.95 (3H; m) ppm. 
13
C NMR (75 MHz, 
DMSO-d6, δ ppm) δ: 162.2, 149.4, 146.2, 138.7, 129.4, 123.7 ppm. Anal. Calcd. (%) for 
C14H9N5O5: C: 51.38; H: 2.77; N: 21.40. Found: C: 51.41; H: 2.77; N: 21.42. 
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(E)-6-((2-(2-hydroxybenzoyl)hydrazono)methyl)benzo[c][1,2,5]oxadiazole 1-oxide 
(12). Yellow powder; yield, 79%; mp, 240 to 241 °C. IR Vmax (cm
-1
; KBr pellets): 3573 
(O-H), 3332 (N-H), 3100 (NH2 amide), 1638 (C=O amide), 1532 (C=N imine), 1484 (N-
O furoxan), 1341 (C-N aromatic). 
1
H NMR (300 MHz, DMSO-d6, δ ppm) δ: 12.12 (1H; 
s), 11.64 (1H; s), 8.51 (1H; s), 7.95 (4H; m), 7.45 (1H; t; J = 7.5 Hz), 6.99 (2H; m) ppm. 
13
C NMR (75 MHz, DMSO-d6, δ ppm) δ: 164.8, 158.7, 145.7, 134.0, 129.0, 119.1, 118.4, 
117.3, 116.3, 113.7 ppm. Anal. Calcd. (%) for C14H10N4O4: C: 56.38; H: 3.38; N: 18.79. 
Found: C: 56.41; H: 3.37; N: 18.80. 
 
(E)-6-((2-(3-hydroxybenzoyl)hydrazono)methyl)benzo[c][1,2,5]oxadiazole 1-oxide 
(13). Yellow powder; yield, 81%; mp, 265 to 266 °C. IR Vmax (cm
-1
; KBr pellets): 3578 
(O-H), 3309 (N-H), 3118 (NH2 amide), 1643 (C=O amide), 1532 (C=N imine), 1371 (N-
O furoxan), 1293 (C-N aromatic). 
1
H NMR (300 MHz, DMSO-d6, δ ppm) δ: 12.15 (1H; 
s), 9.80 (1H; s), 8.50 (1H; s), 7.99 (3H; m), 7.33 (3H; m), 7.00 (1H; d; J = 6.9 Hz) ppm. 
13
C NMR (75 MHz, DMSO-d6, δ ppm) δ: 163.4, 157.4, 144.9, 134.3, 129.6, 119.0, 118.3, 
114.6, 113.3 ppm. Anal. Calcd. (%) for C14H10N4O4: C: 56.38; H: 3.38; N: 18.79. Found: 
C: 56.41; H: 3.38; N: 18.82. 
 
(E)-6-((2-(4-hydroxybenzoyl)hydrazono)methyl)benzo[c][1,2,5]oxadiazole 1-oxide 
(14). Yellow powder; yield, 85%; mp, 280 to 281 °C. IR Vmax (cm
-1
; KBr pellets): 3573 
(O-H), 3332 (N-H), 3096 (NH2 amide), 1638 (C=O amide), 1523 (C=N imine), 1371 (N-
O furoxan), 1280 (C-N aromatic). 
1
H NMR (300 MHz, DMSO-d6, δ ppm) δ: 12.02 (1H; 
s), 10.21 (1H; s), 8.47 (1H; s), 8.01 (2H; m), 7.83 (2H; d; J = 8.7 Hz), 6.87 (3H; d; J = 8.7 
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Hz) ppm. 
13
C NMR (75 MHz, DMSO-d6, δ ppm) δ: 163.0, 161.0, 152.8, 144.0, 136.3, 
130.0, 128.8, 123.4, 118.2, 115.1, 114.8 ppm. Anal. Calcd. (%) for C14H10N4O4: C: 
56.38; H: 3.38; N: 18.79. Found: C: 56.39; H: 3.39; N: 18.78. 
 
(E)-6-((2-(2-aminobenzoyl)hydrazono)methyl)benzo[c][1,2,5]oxadiazole 1-oxide (15). 
Yellow powder; yield, 77%; mp, 193 to 194 °C. IR Vmax (cm
-1
; KBr pellets): 3501 (NH2 
amine), 3319 (N-H), 3100 (NH2 amide), 1668 (C=O amide), 1536 (C=N imine), 1477 (N-
O furoxan), 1346 (C-N aromatic). 
1
H NMR (300 MHz, DMSO-d6, δ ppm) δ: 11.98 (1H; 
s), 8.44 (1H; s), 7.93 (3H; m), 7.59 (1H; d; J = 6.7 Hz), 7.22 (1H; t; J = 7.7 Hz), 6.76 
(1H; d; J = 8.3 Hz), 6.58 (1H; d; J = 7.0 Hz), 6.45 (2H; s) ppm. 
13
C NMR (75 MHz, 
DMSO-d6, δ ppm) δ: 165.6, 152.8, 150.3, 143.8, 132.6, 128.5, 118.2, 116.5, 114.6, 112.7 
ppm. Anal. Calcd. (%) for C14H11N5O3: C: 56.57; H: 3.73; N: 23.56. Found: C: 56.64; H: 
3.74; N: 23.58. 
 
(E)-6-((2-(3-aminobenzoyl)hydrazono)methyl)benzo[c][1,2,5]oxadiazole 1-oxide (16). 
Yellow powder; yield, 82%; mp, 213 to 215 °C. IR Vmax (cm
-1
; KBr pellets): 3501 (NH2 
amine), 3232 (N-H), 3100 (NH2 amide), 1638 (C=O amide), 1532 (C=N imine), 1416 (N-
O furoxan), 1312 (C-N aromatic). 
1
H NMR (300 MHz, DMSO-d6, δ ppm) δ: 12.31 (1H; 
s), 8.86 (1H; s), 8.53 (1H; s), 8.10 (3H; m), 7.87 (3H; s), 7.64 (1H; t; J = 7.9 Hz), 7.57 
(1H; d; J = 7.3 Hz) ppm. 
13
C NMR (75 MHz, DMSO-d6, δ ppm) δ: 162.9, 159.6, 150.5, 
148.9, 145.2, 134.1, 129.7, 128.9, 126.3, 124.6, 120.7, 114.7 ppm. Anal. Calcd. (%) for 
C14H11N5O3: C: 56.57; H: 3.73; N: 23.56. Found: C: 56.59; H: 3.73; N: 23.59. 
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(E)-6-((2-(4-aminobenzoyl)hydrazono)methyl)benzo[c][1,2,5]oxadiazole 1-oxide (17). 
Yellow powder; yield, 84%; mp, 218 to 200 °C. IR Vmax (cm
-1
; KBr pellets): 3478 (NH2 
amine), 3319 (N-H), 3118 (NH2 amide), 1627 (C=O amide), 1500 (C=N imine), 1380 (N-
O furoxan), 1252 (C-N aromatic). 
1
H NMR (300 MHz, DMSO-d6, δ ppm) δ: 8.44 (1H; s), 
7.92 (3H; m), 7.69 (2H; d; J = 8.6 Hz), 6.60 (2H; d; J = 8.6 Hz), 5.87 (2H; s) ppm. 
13
C 
NMR (75 MHz, DMSO-d6, δ ppm) δ: 165.3, 152.6, 142.9, 129.7, 118.9, 112.6 ppm. 
Anal. Calcd. (%) for C14H11N5O3: C: 56.57; H: 3.73; N: 23.56. Found: C: 56.58; H: 3.74; 
N: 23.57. 
 
General procedure for the synthesis of compounds 20-26 
Compound (18) (0.3 g; 1.06 mmol) was dissolved in dichloromethane (15 mL) and then 
cooled by placing it on ice bath. Next, was added the appropriate nitrile (0.15 g; 1.06 
mmol) and potassium carbonate (0.18g; 1.32 mmol) in small portions. The reaction 
mixture was stirred at 40 ºC for 96 hours. After the reaction time, the solvent was 
evaporated under reduced pressure and the obtained solid was dissolved in 50 mL of 
ethyl acetate and washed with water. The organic phase was dried with anhydrous 
magnesium sulfate and the solvent was evaporated giving a yellow solid. The obtained 
solid was purified by silica gel column chromatography using hexane and ethyl acetate 
(70:30 v/v) as eluent to give the appropriate compound 20-26 with variable yields. 
 
3-cyano-6-(1,3-dioxolan-2-yl)-2-(p-tolyl)quinoxaline 1,4-dioxide (20). Yellow powder; 
yield, 9%; mp, 179 to 180 °C. IR Vmax (cm
-1
; KBr pellets): 3090 (C-H aromatic), 2233 
(CN nitrile), 1328 (N-O), 1073 (C-O ether). 
1
H NMR (400 MHz, DMSO-d6, δ ppm) δ: 
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8.55 (2H; t; J = 18.7 Hz), 8.12 (1H; d; J = 8.8 Hz), 7.63 (2H; d; J = 8.0 Hz), 7.43 (2H; d; 
J = 7.9 Hz), 6.10 (1H; s), 4.09 (4H; m), 2.43 (3H; s) ppm. 
13
C NMR (75 MHz, DMSO-d6, 
δ ppm) δ: 143.1, 143.0, 141.1, 136.7, 132.2, 130.1, 129.2, 129.1, 124.7, 121.0, 117.7, 
101.1, 65.3, 21.1 ppm. Anal. Calcd. (%) for C19H15N3O4: C: 65.32; H: 4.33; N: 12.03. 
Found: C: 65.36; H: 4.32; N: 12.05. 
 
2-(4-chlorophenyl)-3-cyano-6-(1,3-dioxolan-2-yl)quinoxaline 1,4-dioxide (21). Yellow 
powder; yield, 13%; mp, 177 to 178 °C. IR Vmax (cm
-1
; KBr pellets): 3091 (C-H 
aromatic), 2235 (CN nitrile), 1330 (N-O), 1093 (C-O ether). 
1
H NMR (400 MHz, 
DMSO-d6, δ ppm) δ: 8.56 (2H; t; J = 16.0 Hz), 8.12 (1H; dd; J = 26.5 Hz), 7.75 (4H; q; J 
= 25.4 Hz), 6.11 (1H; s), 4.09 (4H; m) ppm. 
13
C NMR (75 MHz, DMSO-d6, δ ppm) δ: 
144.8, 142.1, 138.8, 137.1, 136.0, 132.1, 130.8, 128.8, 126.5, 121.1, 117.7, 65.3 ppm. 
Anal. Calcd. (%) for C18H12ClN3O4: C: 58.47; H: 3.27; N: 11.36. Found: C: 58.67; H: 
3.36; N: 11.53. 
 
3-cyano-6-(1,3-dioxolan-2-yl)-2-(4-methoxyphenyl)quinoxaline 1,4-dioxide (22). 
Yellow powder; yield, 26%; mp, 151 to 152 °C. IR Vmax (cm
-1
; KBr pellets): 3085 (C-H 
aromatic), 2236 (CN nitrile), 1335 (N-O), 1095 (C-O ether). 
1
H NMR (400 MHz, 
DMSO-d6, δ ppm) δ: 8.55 (2H; m), 8.05 (1H; dd), 7.71 (2H; d; J = 8.8 Hz), 7.17 (2H; d; J 
= 8.7 Hz), 6.09 (1H; s), 4.08 (4H; m), 3.87 (3H; s) ppm. 
13
C NMR (75 MHz, DMSO-d6, δ 
ppm) δ: 161.2, 144.6, 142.9, 138.8, 132.4, 132.0, 120.6, 119.3, 118.0, 117.7, 113.9, 
101.1, 65.2, 55.4 ppm. Anal. Calcd. (%) for C19H15N3O5: C: 62.46; H: 4.14; N: 11.50. 
Found: C: 62.51; H: 4.15; N: 11.52. 
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3-cyano-6-(1,3-dioxolan-2-yl)-2-(4-fluorophenyl)quinoxaline 1,4-dioxide (23). Yellow 
powder; yield, 30%; mp, 164 to 165 °C. IR Vmax (cm
-1
; KBr pellets): 3077 (C-H 
aromatic), 2234 (CN nitrile), 1330 (N-O), 1097 (C-O ether). 
1
H NMR (400 MHz, 
DMSO-d6, δ ppm) δ: 8.56 (2H; t; J = 17.5 Hz), 8.15 (1H; d; J = 10.4 Hz), 7.81 (2H; t; J = 
14.1 Hz), 7.49 (2H; t; J = 17.7 Hz), 6.10 (1H; s), 4.09 (4H; m) ppm. 
13
C NMR (75 MHz, 
DMSO-d6, δ ppm) δ: 162.2, 143.2, 142.3, 139.1, 136.7, 133.0, 132.9, 132.3, 124.0, 121.0, 
117.7, 115.7, 101.0, 65.3 ppm. Anal. Calcd. (%) for C18H12FN3O4: C: 61.19; H: 3.42; N: 
11.89. Found: C: 61.18; H: 3.41; N: 11.90. 
 
3-cyano-6-(1,3-dioxolan-2-yl)-2-(4-(trifluoromethoxy)phenyl)quinoxaline 1,4-dioxide 
(24). Yellow powder; yield, 3%; mp, 186 to 187 °C. IR Vmax (cm
-1
; KBr pellets): 3077 
(C-H aromatic), 2236 (CN nitrile), 1333 (N-O), 1165 (C-O ether). 
1
H NMR (400 MHz, 
DMSO-d6, δ ppm) δ: 8.57 (2H; t; J = 15.4 Hz), 8.15 (1H; d; J = 8.9 Hz), 7.89 (2H; d; J = 
8.7 Hz), 7.66 (2H; d; J = 8.4 Hz), 6.11 (1H; s), 4.10 (4H; m) ppm. 
13
C NMR (75 MHz, 
DMSO-d6, δ ppm) δ: 149.9, 143.3, 141.9, 139.1, 136.8, 132.7, 132.4, 131.0, 126.7, 121.3, 
121.0, 120.9, 117.7, 101.0, 65.3 ppm. Anal. Calcd. (%) for C19H12F3N3O5: C: 54.42; H: 
2.88; N: 10.02. Found: C: 54.47; H: 2.88; N: 10.06. 
 
3-cyano-6-(1,3-dioxolan-2-yl)-2-(furan-2-yl)quinoxaline 1,4-dioxide (25). Orange 
powder; yield, 26%; mp, 177 to 179 °C. IR Vmax (cm
-1
; KBr pellets): 3087 (C-H 
aromatic), 2240 (CN nitrile), 1355 (N-O), 1107 (C-O ether). 
1
H NMR (300 MHz, 
DMSO-d6, δ ppm) δ: 8.57 (1H; dd; J = 5.2, 3.6 Hz), 8.49 (1H; d; J = 8.9 Hz), 8.24 (2H; d; 
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J = 3.5 Hz), 8.01 (1H; dd; J = 8.9, 1.6 Hz), 6.95 (1H; dd; J = 3.6, 1.8 Hz), 6.08 (1H; d; J 
= 3.1 Hz), 4.09 (4H; m) ppm. 
13
C NMR (75 MHz, DMSO-d6, δ ppm) δ: 146.8, 144.7, 
142.3, 140.2, 138.5, 135.6, 133.4, 132.3, 130.0, 120.9, 117.7, 116.8, 113.2, 111.1, 101.2, 
65.3 ppm. Anal. Calcd. (%) for C16H11N3O5: C: 59.08; H: 3.41; N: 12.92. Found: C: 
59.12; H: 3.42; N: 12.94. 
 
3-cyano-6-(1,3-dioxolan-2-yl)-2-(thiophen-2-yl)quinoxaline 1,4-dioxide (26). Brown 
powder; yield, 15%; mp, 171 to 173 °C. IR Vmax (cm
-1
; KBr pellets): 3092 (C-H 
aromatic), 2241 (CN nitrile), 1357 (N-O), 1084 (C-O ether). 
1
H NMR (300 MHz, 
DMSO-d6, δ ppm) δ: 8.60 (1H; dd; J = 5.3, 3.6 Hz), 8.51 (1H; d; J = 8.8 Hz), 8.45 (1H; 
dt; J = 4.2, 1.2 Hz), 8.13 (1H; dd; J = 5.1, 1.0 Hz), 8.03 (1H; dd; J = 8.9, 1.7 Hz), 7.43 
(1H; dd; J = 5.0, 4.2 Hz), 6.09 (1H; d; J = 3.8 Hz), 4.09 (4H; m) ppm. 
13
C NMR (75 
MHz, DMSO-d6, δ ppm) δ: 145.1, 142.5, 138.1, 137.7, 136.8, 135.6, 132.5, 130.2, 127.0, 
126.0, 120.7, 117.9, 112.6, 101.2, 65.1 ppm. Anal. Calcd. (%) for C16H11N3O4S: C: 
56.30; H: 3.25; N: 12.31. Found: C: 56.31; H: 3.25; N: 12.30. 
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1,8-diazabicyclo[5.4.0]undec-7-ene (DBU); Dichloromethane (DCM); Extensively drug-
resistant (XDR); Food and Drug Administration (FDA); Human immunodeficiency virus 
(HIV); Infrared spectroscopy (IR); Multidrug-resistant (MDR); Minimum bactericidal 
concentration (MBC); Mycobacterium tuberculosis (Mtb); Nuclear magnetic resonance 
(NMR); Quinoxaline 1,4-di-N-oxide (QdNO); Reactive oxygen species (ROS); Resazurin 
microtiter assay (REMA); rifampicin (RMP); Selectivity index (SI); Totally drug-
resistant (TDR); Tuberculosis (TB); World Health Organization (WHO). 
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Scheme 1. Preparation of the compounds of series 1.
a
 
 
a
Reagents and conditions: (a) thionyl bromide, DMF, r.t., 30 min; (b) DBU, 2, 3 or 4- 
hydroxybenzaldehyde, DCM, r.t., 1 h; (c) ethanol, acetic acid, r.t., 12 h. 
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Scheme 2. Preparation of the compounds of series 2.
a
  
 
a
Reagents and conditions: (a) NaN3, DMSO, 75 ºC, 1 h; (b) toluene, reflux, 2h; (c) 
aromatic hydrazide, ethanol, acetic acid, r.t., 12 h. 
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Scheme 3. Preparation of the compounds of series 3.
a
  
 
a
Reagents and conditions: (a) toluene, ethylene glycol, p-toluenesulfonic acid, reflux, 12 
h; (b) DCM, K2CO3, 40 ºC, 96 h; (c) acetone, HCl, r.t., 48 h; (d) isonicotinohydrazide, 
ethanol, acetic acid, r.t., 12 h. 
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Figure 1. Design of the N-oxide containing heterocycles derivatives. 
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Figure 2. Intramacrophage activity of compound (8) and RMP after infection of J774A.1 
macrophages with M. tuberculosis H37Rv (ATCC 27294). The percentage of inhibition 
was determined as the mean of three independent assays. The compounds concentrations 
were: Compound (8) 23.86 µg/mL (4xMIC), 5.84 µg/mL (MIC), 1.46 µg/mL (MIC/4); 
positive control (RMP) 0.064 µg/mL (4xMIC), 0.016 µg/mL (MIC), 0.04 µg/mL 
(MIC/4). Bars: Means±S.D. 
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Figure 3. Time-kill curves of the Compound (8), rifampicin, isoniazid and moxifloxacin: 
results in Log10 CFU/mL of the M. tuberculosis H37Rv (ATCC 27294) according to time 
(days). The CFU count was determined as the mean of three independent assays. The 
compounds concentrations were: 0.72 µM for INH; 0.01 µM for RMP; 0.88 µM for 
MOX and 41.24 µM for Compound 8. Bars: Mean ± S.D. 
  
46 
 
 
Figure 4. In vitro chemical stability. Hydrolytic profile of compound 8 in buffer (pH 5.5 
and 7.4) (data are represented as means ± SEMs and expressed as %). 
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Figure 5. Average frequency of micronucleated reticulocytes (MNRET) and standard 
deviation of 1000 cells obtained from mice treated with the positive control 
cyclophosphamide (50 mg/kg), CMC/Tween (negative control), and compound 8 (50, 
100, 200, and 500 mg/kg body weight). *p < 0.05 (compared to negative control), **p < 
0.05 (compared to the negative control, and compound 8).   
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Figure 6. Results of alanine aminotransferase (6a), aspartate aminotransferase (6b), 
alkaline phosphatase enzyme activity determination (6c) and of urea quantification (6d) 
in the plasma of BALB / c mice. Each compound was administered at a daily oral dose 
(gavage) at a concentration of 200 mg / kg body weight (n = 4 animals / group) and the 
RMP at a concentration of 20 mg / kg. The statistical analysis was performed by Graph 
Pad Prism Version 5.01 software, through Analysis of variance (ANOVA) and Dunnett's 
test, establishing P <0.05 as significance level. Bars: S.D. 
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Figure 7. Histological section of liver stained with H / E from the group treated with 
compound (8). In these groups, histological sections stained with H / E showed, in 
general, presence of hepatocytes with polyhedral morphology, grouped in strings 
separated by sinusoids, forming well-defined hepatic lobes. The sinusoids characterized 
as wall capillaries coated by typical endothelial cells, had some Kupffer cells. In each 
border of the hepatic lobe, there was the presence of well-organized structures called 
portal-space, which is characterized mainly by the presence of portal hepatic vein (PHV), 
arteriole (A) and bile duct (BD). This set was surrounded by a layer of intact and 
continuous connective tissue, which appeared cut off by channels that discharged blood 
into the sinusoids, which flow into the central lobular vein. 
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Figure 8. Histological section of kidneys stained with H / E from the group treated with 
compound (8). Histological sections stained with H / E generally exhibited normal, well 
established and morphologically normal functional units of the kidney. Each nephron had 
the Malpighi corpuscle, characterized by the following structures: 1) Bowman's capsule, 
formed by simple pavement epithelium, and 2) glomerulus (G), characterized by a set of 
capillaries of fenestrated type. Near the Malpighi corpuscle, it was possible to observe 
proximal convoluted tubules formed by a simple layer of high cuboidal epithelial cells, 
which have brush edges facing the light of the tubules. Also adjacent to the Malpighi 
corpuscles were distal tubules formed by low cuboidal cells. 
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Figure 9. Efficacy of compound (8) in microemulsion and controls administrated once 
daily by oral gavage of a 200 µL suspension. Efficacy of 200 mg/kg of compound (8) 
against acute TB in mice. Female 20g BALB/c mice were infected by aerosol with a low 
dose (5x10
6
 CFU/ml) of M. tuberculosis Erdman. Start of treatment commenced at 10 
days postinfection and terminated at 29 days postinfection. Dosages were obtained by 
once-daily dosing by oral gavage. Groups of 7 mice were dosed for 5 consecutive days 
each week. CFU were determined after 3-day washout period at day 31 postinfection. 
Both lungs were homogenized and diluted in Hanks’ balanced salt solution (HBSS)-
Tween, and aliquots were plated on Middlebrook 7H11 medium. Bars: S.D.  *Sterilize 
effect. 
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Figure 10. Genes expression after 4 hours of exposure to compound (8) at 2 times of 
MIC by microarray. (a) Heatmap and (b) Volcano plot, illustrating the effect of 
compound (8) versus vehicle on gene expression in M. tuberculosis H37Rv. (c) Table 
showing two examples of up-regulated genes associated with the ribosome or ATP 
synthase. 
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Table 1. Antitubercular activity of N-oxide containing heterocycles against actively 
replicating and dormant Mycobacterium tuberculosis H37Rv (MIC90); cytotoxicity against 
MRC-5 cell line (IC50); selectivity index (SI) and experimental logP. 
Class Compound 
MIC90  Dormant MIC90 Cytotoxicity IC50 
SI
a
  LogP
b
 
μg/mL μM μg/mL μM μg/mL μM 
Furoxan 
4a 0.16 0.42 2.95 7.72 326.70 854.00 2033.30 1.3 
4b 0.15 0.40 1.60 4.20 490.10 1281.90 3204.70 1.3 
4c 0.16 0.43 0.78 2.04 443.30 1159.50 2696.50 1.3 
Benzofuroxan 
8 0.31 1.10 - 6.62 147.10 519.20 472.0 1.5 
9 2.40 8.30 - - 36.80 130.40 15.60 2.2 
10 1.30 3.90 - - 8.50 25.20 6.30 3.8 
11 1.73 5.29 - - - - - 0.9 
12 16.40 > 62.0 - - - - - 1.3 
13 > 25.0 > 62.0 - - - - - 1.2 
14 > 25.0 > 62.0 - - - - - 1.2 
15 3.70 12.30 - - 36.40 122.40 9.90 2.0 
16 5.30 17.80 - - 24.40 82.10 4.60 1.4 
17 3.16 10.66 >10.0 >10.0 250.0 841.0 78.90 1.2 
Quinoxaline 
19 10.30 30.80 - - 10.70 31.90 0.90 0.7 
20 5.70 16.50 - - 6.20 17.20 1.10 1.6 
21 6.40 16.20 - - 5.00 12.60 0.80 1.8 
22 4.40 12.00 - - 5.50 15.00 1.20 1.4 
23 8.60 24.30 - - 7.70 21.80 0.90 1.3 
24 6.50 15.40 - - 28.00 66.80 4.30 2.2 
25 1.70 5.20 - - 11.60 35.70 6.80 2.0 
26 4.10 12.10 - - 5.90 17.30 1.40 1.9 
28 16.30 39.70 - - 8.60 21.00 0.50 1.0 
Standard 
Drugs 
Isoniazid 0.014 0.1 - 1.108.4 - - - - 
Rifampicin 0.082 0.1 - 0.1 N.D. N.D. N.D. N.D. 
 
a
Abbreviations: SI, ratio between IC50 for MRC-5 and MIC90; dash (-) means not determined. 
b 
Determined 
by partition coefficient (n-octanol/water), HPLC method 
74
. 
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Table 2. Results of MIC (µM) determinations with compound 8 against M. tuberculosis 
H37Rv (ATCC 27294) in three different conditions. 
Compound 
Normal
a
 Acid pH
b
 FBS
c 
BSA
d 
MIC (µM) S.D MIC (µM) S.D MIC (µM) S.D MIC (µM) S.D 
8 5.47 1.01 3.41 1.52 11.79 0.93 9.81 1.21 
Rifampicin 0.05 0.03 0.02 0.02 0.10 0.08 0.10 0.03 
 
a
Normal: normal pH media= 6.8. 
b
Acid pH: adjusted pH media for 6.0. 
c
BFS: 10% bovine fetal serum. 
d
BSA: 4% bovine serum albumin 
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Table 3. Antitubercular activity of N-oxide containing heterocycles against 
Mycobacterium tuberculosis monoresistant strains 
Class Compound 
INHr
a
 RMPr
a
 MOXr
a
 BDQr
a
 CAPr
a
 SMr
a
 
MIC (µM) 
Furoxan 
4a >261.71 0.44 0.81 0.81 >261.71 27.4 
4b >261.71 2.31 1.22 2.56 >261.71 >261.71 
4c >261.71 1.99 0.66 6.38 >261.71 >261.71 
Benzofuroxan 8 8.59 3.78 5.72 1.20 15.25 16.98 
Standard 
Drugs 
RIF 0.01 >1.00 0.10 0.04 0.21 0.03 
INH >5.0 0.35 0.28 0.23 >5.00 >5.00 
MOX 0.23 0.12 >8.00 0.26 0.35 0.36 
BDQ 0.01 0.01 0.06 1.70 0.06 0.06 
CAP - - - - 60.46 1.72 
SM - - - - 2.55 >100 
a
Abreviations: (INHr) isoniazid resistant; (RMPr) rifampicin resistant; (MOXr) moxifloxacin resistant; 
(BDQr) Bedaquiline resistant; (CAPr) capreomycin resistant and (SMr) streptomycin resistant. Dash (-) 
means not determined. 
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Table 4. In vitro ADMT data for compound 8 
Assay Compound 8 
Human plasma protein binding (% free) 46.5 
Caco-2 permeability 
 
A−B Papp
a 
(cm/s) 5.67 x 10
-6
 
B−A Papp
a
 (cm/s) 3.90 x 10
-6
 
CYP inhibition IC50 (µM) 
 
CYP2B6 > 20 
CYP2C8 > 20 
CYP2C19 15.3 
CYP3A4 > 20 
HepG2 IC50 (µM) 16 
a
Papp is the apparent permeability rate coefficient. 
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Table 5. Plasma levels of compound (8) (300 mg/kg dose), RMP-ME and RMP-CMC (dose of 20 mg/kg) following a single 
administration through oral route at times: 0,3h; 1h; 2h and 4h. Experiments were carried out in BALB/c mice. 
Compound 
Standard
a
 
Drug Dose 
(mg/kg/body) 
Mice Data
b
 
0,3 h 1 h 2 h 4 h 
MIC (µg/mL) 
predetermined 
Inhibition 
(%) 
Estimate 
(µg/mL) 
Inhibition 
(%) 
Estimate 
(µg/mL) 
Inhibition 
(%) 
Estimate 
(µg/mL) 
Inhibition 
(%) 
Estimate 
(µg/mL) 
Compound (8)-ME 5.84 300 65.67 42.61 79.00 51.26 76.00 49.31 51.33 33.30 
RMP-ME 0.015 20 66.33 0.11 63.00 0.31 76.33 0.37 91.00 0.15 
RMP-CMC 0.015 20 73.67 0.11 84.00 0.14 62.27 0.10 68.00 0.11 
a
Predetermined by Resazurin Microtiter Assay (REMA) in vitro. 
b Determined using plasma mice by REMA in vitro, estimative in plasma. 
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